In France and all around the world, many different dose regimens (200 to 1200 mg daily, one to three times daily, with or without a loading dose) of hydroxychloroquine have been used and are recommended for COVID-19 infection treatment (Table [1](#dkaa191-T1){ref-type="table"}). In many sites and countries, clinicians use dose regimens recommended for chronic autoimmune disease treatment, such as rheumatoid arthritis or systemic lupus erythematosus. The objective and exigencies of a short-term course of hydroxychloroquine treatment against COVID-19 infection are, however, quite different from the usual chronic autoimmune disease treatment. A large number of clinical trials are being initiated all around the world to evaluate the efficacy and toxicity of this drug in this infection. It is important for these trials to use hydroxychloroquine doses based on a specific scientific rationale.

###### 

Clinical trials evaluating hydroxychloroquine in COVID-19 prevention or treatment using a loading dose

  Study identifier            Sponsor                                                                          Phase  Primary purpose          Day 1           Maintenance dose     Maintenance daily dose   Duration of treatment
  --------------------------- ------------------------------------------------------------------------------- ------- ----------------- -------------------- --------------------- ------------------------ -----------------------
  NCT04323631                 Rambam Health Care Campus                                                          1    treatment          400 mg twice daily   200 mg twice daily            400 mg                  10 days
  NCT04318444                 Columbia University                                                                2    prevention         400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04303507                 University of Oxford                                                              NA    prevention           10 mg base/kg       200 mg once daily            200 mg                  90 days
  (COPCOV)                                                                                                                                                                                                  
  NCT04321616                 Oslo University Hospital                                                           2    treatment          800 mg twice daily   400 mg twice daily            800 mg                  10 days
  (SOLIDARITY)                                                                                                                                                                                              
  NCT04315948                 Institut National de la Santé Et de la Recherche Médicale, France                  3    treatment          400 mg twice daily    400 mg once daily            400 mg                  10 days
  (DISCOVERY)                                                                                                                                                                                               
  NCT04304053                 Fundacio Lluita Contra la SIDA                                                     3    prevention         800 mg once daily     400 mg once daily            400 mg                  7 days
  (HCQ4COV19)                                                                                                                                                                                               
  NCT04308668                 University of Minnesota                                                            3    treatment          1400 mg once daily    600 mg once daily            600 mg                  5 days
  (COVID-19 PEP)                                                                                                                                                                                            
  NCT04325893                 University Hospital, Angers                                                        3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  8 days
  (HYCOVID)                                                                                                                                                                                                 
  2020-001113-21 (RECOVERY)   University of Oxford                                                              2/3   treatment          800 mg twice daily   400 mg twice daily            800 mg                  10 days
  NCT04342221                 University Hospital Tübingen                                                       3    treatment          800 mg once daily     600 mg once daily            600 mg                  7 days
  (COV-HCQ)                                                                                                                                                                                                 
  NCT04342156                 Tan Tock Seng Hospital                                                             3    prevention         800 mg once daily     400 mg once daily            400 mg                  5 days
  (SHARP COVID-19)                                                                                                                                                                                          
  NCT04342169                 University of Utah                                                                 2    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04341441                 Henry Ford Health System                                                           3    prevention         400 mg once daily     200 mg once daily            200 mg                  8 weeks
  (WHIP COVID-19)                                                                                                                                                                                           
  NCT04339816                 Charles University, Czech Republic                                                 3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (AZIQUINE-ICU)                                                                                                                                                                                            
  NCT04338906                 Heinrich-Heine University, Duesseldorf                                             4    treatment          400 mg twice daily   200 mg twice daily            400 mg                  7 days
  (CLOCC)                                                                                                                                                                                                   
  NCT04335552                 Duke University                                                                    2    treatment          800 mg once daily     600 mg once daily            600 mg                  5 days
  NCT04334967                 Providence Health & Services                                                       4    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04334382                 Intermountain Health Care, Inc.                                                    3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (HyAzOUT)                                                                                                                                                                                                 
  NCT04332991                 Massachusetts General Hospital                                                     3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (ORCHID)                                                                                                                                                                                                  
  NCT04332094                 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau             2    treatment          400 mg twice daily   200 mg twice daily            400 mg                  7 days
  (TOCOVID)                                                                                                                                                                                                 
  NCT04330144                 Gangnam Severance Hospital                                                         3    prevention         800 mg once daily     400 mg once daily            400 mg                  5 days
  (HOPE Trial)                                                                                                                                                                                              
  NCT04329832                 Intermountain Health Care, Inc.                                                    2    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (HAHPS)                                                                                                                                                                                                   
  NCT04329611                 University of Calgary                                                              3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04329572                 Azidus Brasil                                                                      1    treatment          400 mg twice daily    400 mg once daily            400 mg                  5 days
  ChiCTR2000029898            Peking University Third Hospital                                                   4    treatment          600 mg twice daily   200 mg twice daily            400 mg                  5 days
  IRCT201002280 03449N30      Tehran University of Medical Sciences                                             2/3   treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04328012                 Bassett Healthcare                                                                 3    treatment          400 mg twice daily   200 mg twice daily            400 mg                5--14 days
  (COVIDMED)                                                                                                                                                                                                
  NCT04328272                 Ayub Medical College, Abbottabad                                                   3    treatment          600 mg twice daily   400 mg twice daily            800 mg                  7 days
  NCT04345861                 University Hospital, Montpellier                                                  2/3   treatment          800 mg once daily     600 mg once daily            600 mg                  10 days
  (COVIDOC)                                                                                                                                                                                                 
  NCT04328285                 Centre Hospitalier Universitaire de Saint Etienne                                  3    prevention         400 mg twice daily    200 mg once daily            200 mg                  60 days
  (COVIDAXIS)                                                                                                                                                                                               
  NCT04347512                 University Hospital, Strasbourg, France                                            3    treatment          400 mg once daily     200 mg once daily            200 mg                  5 days
  (TEACHCOVID)                                                                                                                                                                                              
  NCT04345692                 Queen's Medical Centre                                                             3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (OAHU-COVID19)                                                                                                                                                                                            
  NCT04346667                 Government of Punjab, Specialized Healthcare and Medical Education Department      4    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  (PEACE)                                                                                                                                                                                                   
  NCT04344444                 LCMC Health                                                                        3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04341727                 Washington University School of Medicine                                           3    treatment          400 mg twice daily   200 mg twice daily            400 mg                  5 days
  NCT04334148                 Duke University                                                                    3    prevention         600 mg twice daily    400 mg once daily            400 mg                  30 days
  (HERO-HCQ)                                                                                                                                                                                                
  NCT04333654                 Sanofi                                                                             1    treatment           800 mg + 400 mg     200 mg thrice daily           600 mg                  10 days
  2020-001270-29              Sanofi                                                                            2/3   treatment           800 mg + 400 mg     200 mg thrice daily           600 mg                  10 days

NA, not applicable.

Based on the severe acute respiratory distress syndrome (ARDS) reported, marked by an uncontrolled cytokine release, eradication of the novel coronavirus (SARS-CoV-2) that causes COVID-19[@dkaa191-B1] requires rapid drug penetration into pulmonary tissues, intracellular drug uptake and anti-inflammatory[@dkaa191-B2] and immunomodulatory effects.[@dkaa191-B1]

Among the different candidates for COVID-19 infection treatment, hydroxychloroquine is a racemic 4-aminoquinoline derivative, chemically related to chloroquine but less toxic in animals,[@dkaa191-B3] used as the sulphate salt for oral administration (200 mg hydroxychloroquine sulphate is equivalent to 155 mg hydroxychloroquine base) and demonstrating favourable *in vitro* antiviral activity against SARS-CoV-2.

Hydroxychloroquine was found to decrease viral replication in a concentration-dependent manner *in vitro* \[EC~50~ of 0.72 μM (242 ng/mL) at 48 h\] and to be more active when added prior to the viral challenge.[@dkaa191-B4] Hydroxychloroquine effectively inhibited the entry step, as well as the post-entry stages of SARS-CoV-2 infection, by changing the glycosylation of the ACE2 receptor and the spike protein.[@dkaa191-B5]

Besides its antiviral activity, hydroxychloroquine is also known for its modulation of the immune response. In particular, hydroxychloroquine can increase the intracellular pH and inhibit lysosomal activity in antigen-presenting cells, reducing T cell activation, differentiation and expression of co-stimulatory proteins (e.g. CD154 on CD4+ T cells) and cytokines produced by T cells and B cells (e.g. IL-1, IL-6 and TNF). Hydroxychloroquine can also interrupt binding between toll-like receptors (TLR7 and TLR9) and their RNA/DNA ligands and interfere with the interaction between cytosolic DNA and the nucleic acid sensor cyclic GMP-AMP synthase, attenuating the subsequent pro-inflammatory signalling activation and production of cytokines, such as IL-1 and TNF.[@dkaa191-B1]

Following oral dosing, hydroxychloroquine is rapidly and extensively absorbed, with a time to maximum blood concentration achieved in approximately 4 h. Oral absorption of hydroxychloroquine sulphate tablets is not stereoselective and comparable fractions of each enantiomer are absorbed (74% of the dose for the R enantiomer compared with 77% for the S enantiomer).[@dkaa191-B6] According to the Plaquenil label information,[@dkaa191-B7] under normal circumstances and because they are film-coated, tablets should not be crushed or cut in half. In the exceptional case of a nasogastric tube for patients in the ICU, tablets might be crushed after removal of the film coating and dispersed slowly in water before administration.[@dkaa191-B8] Absorption of any altered hydroxychloroquine formulation should be verified with therapeutic drug monitoring when available.

Hydroxychloroquine, as a weak base, demonstrates an extensive volume of distribution attributed to tissue uptake by ion trapping rather than tissue binding.[@dkaa191-B9] It enters erythrocytes via passive diffusion and accumulates in blood cells, with a mean (SD) blood to plasma ratio of 7.2 ± 4.2.[@dkaa191-B10] Approximately 50% of hydroxychloroquine is bound to plasma proteins.

Hydroxychloroquine is mainly metabolized to *N*-desethyl-hydroxychloroquine and two other metabolites in common with chloroquine, desethyl-chloroquine and bidesethyl-chloroquine.[@dkaa191-B3] The metabolism of hydroxychloroquine is known to be stereoselective, favouring the metabolism of (+)-(S)-hydroxychloroquine. The hepatic extraction ratio of racemic hydroxychloroquine from blood is very low (0.06), suggesting that first-pass hepatic extraction accounts for only 6% of the administered dose.[@dkaa191-B10] Based on animal studies, the rest of the hydroxychloroquine is extensively distributed in tissues such as muscles, eyes, heart, kidneys, liver, spleen and lungs, where sequestration is prolonged.[@dkaa191-B3]

To date, the specific metabolic pathways of hydroxychloroquine are unknown and considered likely to be similar to those of chloroquine. By extrapolation, human P450 enzymes such as CYP2D6, -2C8, -3A4 and -3A5 are believed to be the major enzymes responsible for the *N*-desethylation of hydroxychloroquine.[@dkaa191-B11] Whether genotypic polymorphism in these oxidative enzymes affects the antiviral efficacy or toxicity of hydroxychloroquine is still unknown.

The very long mean ± SD terminal elimination half-life of hydroxychloroquine (50 ± 16 days)[@dkaa191-B12] appears to be mainly due to its extensive volume of distribution (5522 L, estimated from blood data),[@dkaa191-B10] which is consistent with the lipophilicity of the hydroxychloroquine molecule (logP = 3.84).[@dkaa191-B4] Based on pharmacokinetic predictions in healthy volunteers, a period of 6 months on oral hydroxychloroquine sulphate 200 mg tablets once daily is required to achieve 96% steady-state concentrations of hydroxychloroquine.[@dkaa191-B12] Elimination is predominantly via the faeces, with approximately 20%--25% of the dose excreted as unchanged drug in the urine.

A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. With some drugs, especially those with a large volume of distribution such as hydroxychloroquine, it may be necessary to give a large dose initially to get above the minimum effective concentration and get the beneficial effect quickly. However, the loading dose will not maintain the target concentration unless an appropriate maintenance dose is also used. Theoretically, this loading dose is calculated by multiplying the desired target drug concentration by the volume of distribution of the drug.

In the case of hydroxychloroquine, the desired target concentration might be the EC~50~ against SARS-CoV-2 (242 ng/mL) and we used the volume of distribution (5522 L) for a calculated loading dose of approximately 1336 mg at Day 1. According to the within-subject variability, this volume of distribution is very close to the apparent volume of distribution (*V*~ss~/F) estimated by Ducharme *et al*.[@dkaa191-B13] (7760 ± 4480 L). Based on the oral galenic formulation available for hydroxychloroquine sulphate (200 mg film-coated tablets), the loading dose might be 600 mg twice daily to approach the calculated loading dose.

Based on results obtained by simulation using a physiologically based pharmacokinetic (PBPK) model that can predict hydroxychloroquine concentrations in human lung tissues *in silico*,[@dkaa191-B4] several dosing regimens for hydroxychloroquine sulphate including a loading dose were evaluated. They showed that plasma concentrations of hydroxychloroquine rapidly increased after each of the three different regimens of loading dose (800 + 400 mg versus 600 + 600 mg versus 400 + 400 mg at Day 1) followed by different maintenance doses. Moreover, the free lung tissue inhibitory quotients (IQs) for hydroxychloroquine (ratio of free lung tissue trough concentration to EC~50~) were calculated for the different regimens. The regimen consisting of 400 mg twice daily at Day 1 (loading dose) then 200 mg twice daily from Day 2 to Day 5 (maintenance dose) was expected to achieve a free lung IQ of 21 on the first day, 39 on the third day and 85 on the tenth day. Owing to the uncertainty surrounding the *in vitro* susceptibility of SARS-CoV-2, particularly in pulmonary tissue, we decided to choose the longer option of treatment, given the best ratio of free lung tissue trough concentration to EC~50~ of 85 for 5 day and 154 for 10 day treatment durations.

The same maintenance dose was previously tested by Furst *et al.*[@dkaa191-B14] as the daily dose indicated in active rheumatoid arthritis, where mostly gastrointestinal adverse events occurred during the first 6 weeks of treatment. According to the discontinuations for adverse effects being proportionally related to the cumulative dose (16 800 mg) in that study, the lower loading dose of 400 mg q12h and a maintenance dose of 400 mg q24h for a 10 day treatment duration (cumulative dose of 4400 mg) were chosen in the C-20-15 DisCoVeRy study (NCT04315948).

In the light of these pharmacological, virological and safety data from the literature, we believe that our hydroxychloroquine dosing regimen should be evaluated in a multicentre, adaptive, randomized clinical trial versus lopinavir/ritonavir, with or without β-1b IFN, versus remdesivir versus standard of care for the treatment of adults hospitalized with COVID-19.
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